Transform mental health treatment with one easy tool
The Neuropharmagen® Difference
Overview
What is Neuropharmagen®?
Precision Genetics is a healthcare technology company that leverages genetic diagnostics and data analytics to provide prescribing solutions and improve patient outcomes.
Precision Genetics’ Neuropharmagen® is a genetically guided decision support tool that helps healthcare professionals provide safer and more effective treatment to patients suffering from mental health disorders. Neuropharmagen® integrates patient genetic data and published drug-drug interactions with patient comorbidities, chronic diseases, and lifestyle factors to deliver a comprehensive view of a particular drug’s likely effects. Neuropharmagen® can integrate with existing workflows to streamline personalized medicine and reduce the unacceptably high number of adverse drug reactions within mental health care.
42%
of the variability in response to antidepressants is associated with genetic variants
A Tool Whose Time Has Come
Neuropharmagen® enables personalized medicine, which is a crucial step in identifying which drugs work best for which patients, and which drugs may pose a safety risk. In psychiatry, approximately 42% of the variability in response to antidepressants is associated with genetic variants.1 Further complicating the treatment path in depression, about 10% of patients discontinue an antidepressant due to side effects.2
Evidence in Clinical Settings
Genetic testing panels are available for many psychotropic drug classes, including antidepressants (e.g., SSRIs), antipsychotics, anxiolytics (e.g., benzodiazepines), stimulants, and addiction treatments (e.g., buprenorphine).
In a study of 450 patients with major depressive disorder, genetic-guided prescribing with Neuropharmagen® led to a 1.8-fold increase in the odds of clinical response versus unguided drug selection. Separately, a study of 316 patients with major depressive disorder found a significant decrease in the burden of side effects for patients who received Neuropharmagen®-guided treatment compared to patients who were treated as usual (FIBSER Burden score ≤2, i.e., no general need to address side effects: Neuropharmagen® group, 66.7%; standard care group, 50.0%; odds ratio = 2.0 [95% CI: 1.1, 3.8]).3
Clinical Workflow Integration
The Neuropharmagen® interface was developed with input from a panel of psychiatrists to ensure ease of use. This solution can be integrated seamlessly into existing EHR and other laboratory information management systems at all touchpoints in the clinical journey. Clinicians can order a test, link a patient’s profile and history, and view the genetic results within an EHR.
Access to Full-Service Support
Precision Genetics reduces the administrative burdens on clinicians and practices by providing support teams who assist throughout the entire ordering process. We also work directly with insurance carriers to determine coverage of the test. Testing is covered by various private insurance, traditional Medicare, and Medicare Advantage plans and may vary depending on the plan.
Streamline Treatment Plans with Neuropharmagen®
When the choice of psychiatric medication is individualized and optimized based on genetic-guided test results, patients are less likely to experience side effects and have better adherence to treatment plans. Neuropharmagen® offers the opportunity to match patients to a suitable therapy earlier in the course of their treatment, reducing the amount of trial and error for the patient and the clinician.
View real-world cases and success stories
After years of trying and failing to get relief, Perla had Neuropharmagen® genetic-guided testing and is now responding to treatment with a drug for major depression.
See how Dr. Brittany Albright implemented Neuropharmagen® genetic-guided testing as a regular part of clinical practice, with the help of the Precision Genetics customer service team.
Personalized prescribing solutions
Precision Genetics is dedicated to a new, more efficient standard of care that increases positive patient outcomes for mental health disorders by treating them with precision. Neuropharmagen® combines evidence-based pharmacogenomic and pharmacology data with comprehensive patient-specific data to offer a truly personalized roadmap for patient care.
Neuropharmagen® provides guidance and information on a wide range of psychoactive drugs for which relevant scientific evidence on pharmacogenetics is available.
Neuropharmagen® analyzes over 60 genetic polymorphisms in 26 genes, selected in accordance with the available pharmacogenetic evidence.
Interactive, easy-to-read report
Neuropharmagen® reports feature an easy-to-interpret color coding system to highlight gene-drug interaction alerts, and visual icons for drug-drug and drug-clinical-physiological interactions.
How to Order Neuropharmagen®
Ordering a Test Is Seamless
To initiate an order, simply follow these three easy steps:
Step 1: Complete Online Form
Start by completing our online form with your provider credentials, practice, and contact information.
Step 2: Receive Aina Portal Login
Within 24 hours, one of our customer service representatives will contact you to help set up your Aina portal account for ordering.
Step 3: Begin Ordering Tests
Order your test through the Aina provider portal. Collection kits will go directly to the patient, and you’ll be notified once report results are ready.
Only healthcare professionals who are licensed and capable of prescribing medication may order a Neuropharmagen® test. Patients can ask their healthcare professional to facilitate ordering a test and then review the results together. Our goal is to ensure a hassle-free experience from start to finish.
Learn More With Our White Papers
Take a deeper dive into the current mental health treatment crisis and the evidence for a genetic-guided testing solution.
Primary care
Transforming Mental Health at the Front Line: Using Data-Driven Genetic Insights in Primary Care
Psychiatry
Precision Psychiatry: How Data-Driven Solutions are Transforming Medication Management
Opt-in to Future News and Insights
1Tansey KE, et al. “Contribution of common genetic variants to draw response.” Biol Psychiatry. 2013 Apr 1; 73(7): 679-82.
2Zhang JP, Malhotra AK. “Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.” Expert Opin Drug Metab Toxicol. 2011. 7(1): 9-37.
3Precision Genetics. https://precisiongenetics.com/clinical-trials-data/